About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Dr. Stefanacci explains the new rules for Medicare’s Part D drug benefit for the year 2007 and offers strategies for reducing out-of-pocket expenses for beneficiaries.
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Augmentation and Combination Pharmacotherapy Trends in Major Depressive Disorder: Results of a Brief Survey of Psychiatrists
The authors present the results of a brief audience participation survey of 601 psychiatrists about their practices of prescribing antidepressants and discuss the use of first-line, second-line, and third-line treatment options.
Thomas L. Schwartz, MD, and Ayesha Rashid, MD
Managing Hypertension in Patients with or without Comorbidities in a Teaching Hospital Outpatient Setting
Patients were able to achieve reductions of blood pressure, glycosylated hemoglobin, and low-density lipoprotein-cholesterol, according to the authors, because physicians adhered to national guidelines and spent “quality time” with these patients.
Shan Wang, PharmD, RPh, Nicholas Berbari, MD, David Choi, DO, James McNamara, PharmD Candidate, Martin Feuerman, MS, Kathryn Bucci, PharmD, and Brian Malone, MS, RPh
Dr. Goldenberg discusses the current status of targeted therapies for colorectal cancer; novel biologic agents that target angiogenesis and growth factors; a monoclonal antibody for colon and pancreatic cancer; and kinase-targeted drugs for gastrointestinal stromal tumors.
Marvin M. Goldenberg, PhD, RPh, MS
The authors review the cardiovascular risks of commonly used painkillers and present the latest findings on acute myocardial infarction, atrial fibrillation in hypertension, cardiovascular disease in diabetes patients, non–ST-segment elevation in acute coronary syndrome, and familial hypercholesterolemia. The controversial torcetrapib/atorvastatin (Lipitor) combination is also discussed.
Lawrence M. Prescott, PhD, and Sharon L. Prescott
David Nash, MD, MBA, describes the Pacific Northwest Economic Region (PNWER), an alliance of states and territories that offers publicly funded health insurance in Canada.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, explains how “systems thinking” can be used to prevent errors like the tragic accident in 2001 that killed a young MRI patient.
Matthew Grissinger, RPh, FASCP
With New Commissioner Aboard, Congress and the FDA Will Emphasize Postmarketing Surveillance and Adverse Reactions
Stephen Barlas discusses the challenges that face the new FDA Commissioner and Congress in 2007, especially the need to strengthen the FDA’s MedWatch system and its reporting of adverse drug events.
P&T presents the latest studies and information about FDA approvals, drug indications, and industry updates.
The authors review varenicline (Chantix) for smoking cessation.
Marilena S. Antonopoulos, PharmD, and Christine M. Bercume, PharmD